CCL1 in therapy

Researcher:

Categories:

Pharmaceuticals and Biotechnology

The Technology

In inflammatory autoimmune disease such as Inflammatory Bowels diseases (IBD) Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and others the activity of effector autoimmune T cells is tightly regulated by FOXp3+ regulatory T cells (Tregs). CCL1 is a chemokine with a very short half-life time (in vivo) that exclusively potentiates the activity of these cells. We have generated a CCL1-Ig based fusion protein (also referred to as CCL1-Fc) with a substantially longer half-life in vivo (PK) and a very long in vivo activity (PD) that function as an agonistic molecule for FOXP3+ Tregs and effectively suppresses ongoing autoimmunity.

Advantages

  • Effectively treats different autoimmune diseases in experimental models (EAE, IBD)
  • As an agonistic molecule, has a long half life time
  • Likely to have low toxicity
  • Robust in vitro and ex-vivo assays relevant to the MOA of the drug.

Applications and Opportunities

  • Autoimmunity, chronic inflammation
arrow Business Development Contacts
Motti Koren
Director of Business Development, Life Sciences